Bionest

Expanding the CRISPR Toolbox for New Healthcare Applications

CRISPR/Cas9 was first successfully demonstrated as a tool for genome editing in human cells in 2013.  Since then, several advances have enabled the use of this technology to shut down a faulty gene, change a single DNA letter in a gene sequence, or add a new gene to an existing genome sequence. This summer has...

Bionest

AI Aiding Earlier, More Accurate Cancer Screening

Recent research clearly illustrates the potential that artificial intelligence (AI) and deep learning systems offer for improving the detection and diagnosis of cancer, whether from radiological images or tissue analysis. While further clinical validation of such systems is needed before they can be reliably deployed in medical practice, they are expected to benefit patient care...

Bionest

Wearables Evolve from Wellness to Clinical Medicine

Wearables – including consumer products like FitBit wristbands and smartwatches – are quickly moving beyond their use as wellness products that track steps and sleep patterns to incorporate serious medical device capabilities and clinical applications.   In September 2018, the Apple Series 4 model smartwatch became the first such product to have its software officially...

Bionest

The Changing World of Medical Marketing

A recent survey published in the Journal of the American Medical Association (JAMA) reported that the medical marketing spend in the United States rose from approximately $17.7 billion in 1997 to just under $30 billion in 2016. The biggest growth came from Direct-to-Consumer (DTC) marketing, which increased from 11.9% to 32% of the total spend....

Bionest

Artificial Intelligence and Image-Based Diagnostic Tools

We have recently been hearing much about “machine learning” and “artificial intelligence” (A.I.). While many tend to use the two terms almost interchangeably, there is a distinct difference between the two.   Machine learning, also known as “deep learning,” is a field of applied mathematics that uses algorithms and statistical models to build predictive systems...

Bionest

No Signs of Slowdown in NGS Sequencing Market

A couple of recent announcements in the next-generation sequencing (NGS) market got our attention as strong signs that both technology and applications are rapidly diversifying within that arena. It’s continued evidence that the NGS market is not only expanding rapidly, but also that there are no limits in sight to the demand for genomic information....